Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2016-12-01 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
国金证券股份有限公司关于公司2015年度定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a '2015年度定期现场检查报告' which translates to '2015 Annual Regular On-site Inspection Report' by Guojin Securities Co., Ltd. for Shandong Ruikang Pharmaceutical Co., Ltd. The content focuses on detailed inspection of corporate governance, internal controls, information disclosure, use of raised funds, and compliance with laws and regulations. It includes checklists and findings from an on-site inspection rather than financial statements or audit opinions. The document is about regulatory compliance and inspection results rather than a full annual report, audit report, or financial statement. It is not a short announcement or certification but a substantive inspection report. This fits best with the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests excluding full annual reports. Therefore, the classification is AR with high confidence. H2 2015
2016-12-01 Chinese
关于实际控制人进行股票质押式回购交易的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the stock pledge and repurchase transactions by the actual controller of the company, including details about pledged shares, dates, and pledgees. It does not contain financial statements, earnings data, or management discussion. It is a disclosure about share transactions by a major shareholder or director. This fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2016-12-01 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding by TB NATURE LIMITED in 瑞康医药股份有限公司, including the number of shares held before and after the change, the method of share disposal (block trades), and the legal and regulatory basis for the disclosure. The document includes detailed information about the shareholder, the shareholding changes, and compliance with securities laws. This type of document is a notification of changes in major shareholding levels, consistent with the definition of Major Shareholding Notification (MRQ). It is not an annual report, earnings release, or any other financial report, but a regulatory disclosure about shareholding changes. The document length (6500 characters) and content confirm it is a full report of shareholding changes, not just an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is MRQ with high confidence.
2016-11-07 Chinese
第三届监事会第一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the first meeting of the third Supervisory Board of Ruikang Medicine Co., Ltd. It includes the election of the Supervisory Board Chairman and the approval of the company's 2016 third quarter report. The document is short (738 characters) and primarily serves as a notice of the meeting's decisions rather than the full quarterly report itself. It explicitly states the approval of the '2016 third quarter report (full text and main text)' but does not contain the report's financial data or detailed analysis. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement related to corporate governance and report approval, not the report itself.
2016-10-26 Chinese
2016年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 Third Quarter Report" of 瑞康医药股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as balance sheet items, profit and loss statement items, cash flow statement items, and explanations of changes in financial metrics compared to previous periods. The document also includes shareholder information and management's discussion of financial performance and outlook for the year 2016. The length of the document (over 10,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2016
2016-10-26 Chinese
第三届董事会第一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the first meeting of the third board of directors of 瑞康医药股份有限公司 (Realcan Pharmaceutical Co., Ltd.). It includes election and appointment of the chairman, vice chairman, various board committees, general manager, deputy general managers, board secretary, financial director, and securities affairs representative. It also mentions the approval of the 2016 third quarter report but does not contain the report itself. The document is primarily about board and senior management appointments and related governance matters. It is not a full annual or quarterly report, audit report, or earnings release. The content fits the category of Board/Management Information (MANG) as it announces changes in the company's board of directors and senior management. The document length (5353 characters) and detailed content support this classification with high confidence.
2016-10-26 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.